| Aug 16 |
Mangoceuticals files to sell 16.17M shares of common stock for holders
|
| Aug 16 |
Mangoceuticals reports 1H results
|
| Aug 15 |
MangoRx Reports 1,685% Increase in Shareholders’ Equity From December 31, 2023, to $13.8MM, and 56% Increase in Year-Over-Year Revenue for First Half of 2024
|
| Aug 9 |
MangoRx Completes Migration to DEA-Approved Telemedicine Platform, Accelerating Timeline of Oral Dissolvable GLP-1 Weight Loss Treatments Featuring Semaglutide and Tirzepatide
|
| Aug 8 |
MangoRx Receives Request for Proposal (RFP)Â From ISFLST for New Male Enhancement Product Exclusive for the Asian Market
|
| Jul 24 |
MangoRx Initiates Efficacy Studies on its Patented Respiratory Illness Prevention Technology
|
| Jul 18 |
Mangoceuticals CEO Jacob Cohen Featured on Benzinga All-Access
|
| Jul 16 |
MangoRx Secures DEA Approval for Proprietary HIPAA-Compliant Operating System via Surescripts
|
| Jul 12 |
MangoRx Appoints Dr. Douglas Christianson, N.D. as Director of the Medical Research and Product Innovation Department
|
| Jul 11 |
MangoRx signs partnership for expansion into Asia Pacific, China and Latin America
|
